Every day over 22,000 people in the World die because of cancer.
Early diagnostics often plays the key role in cancer therapy. Many patients can be cured
if the tumor is detected on the early stage of growth.
That is why NanoThea is developing a novel effective and low cost tool for early diagnostics of solid tumors.
As Henry Ford once wished to
build a car for everybody
our mission is to give every patient
chance for a reliable and precise diagnostics and early cancer detection.
To create nanoparticle that reaches even first few tumor cells
and join forces to accelerate it to every hospital.
NanoThea is a group of full of passion scientists and business professionals.
We started as a group of scientists seeking to improve available ways to fight cancer.
In multidisciplinary mashup of biologists, chemists and process engineers we developed nanoparticles using natural materials compatible with human organism. The potential of NanoThea technology has been recognized by two VC companies. We strongly believe that our technology is the future of diagnostic oncology.
Since 2012 we started to work on nanotechnology for cancer treatment and diagnosis.
In BioMedical Engineering Laboratory, established by prof. Tomasz Ciach at Warsaw University of Technology, we developed novel nanoparticles for cancer treatment using chemotherapeutics.
As a step forward after our first adventure with encapsulating drugs inside nanoparticles we decided to create nanoparticles for cancer diagnostics. We focused our research on two methods: fluorescence and radioisotopes. With combining these two methods we are able to track on-line the fate of nanoparticle in the organism. Thanks to radioisotopes even small signal from few cancer cells is visible on the PET scan. Our ideas and attitude attracted attention of two VC companies. In September 2015, together with Giza Polish Ventures and StartVenture@Poland we founded NanoThea to commercialize the innovative tool for cancer diagnostics. Now we are working to go global with our idea.
PhD hab., Associated Professor
at Warsaw University of
Technology, specialist in the field
of Biomedical Engineering,
inventor of three products
introduced to the market,
author of more than 20 patents
and patent applications.
Biotechnologist, PhDc on Warsaw
University of Technology, specialist
in nano-solutions for cancer treatment.
Gathered her experience on
and in NanoVelos Start-up research team.
Chemist, graduated from
Chemical Department of Warsaw
University of Technology.
Member of BioMedical
at the Faculty of Chemical
and Process Engineering WUT.
Biotechnologist, PhDc at Warsaw
University of Technology, member
of BioMedical Engineering
Laboratory at the Faculty of
Chemical and Process
graduated from Mechatronic Department of Warsaw
University of Technology, Mechanical Department
of Lublin University of Technology and
Medical Department of Medical University of Lublin,
An entrepreneur, founder
of Internet businesses.
Experienced in setting up
new life science businesses.
Partner at Polish-Israeli
VC – Giza Polish Ventures.
Diplomat, a specialist in the field
of Marketing, Media Relations,
Strategic Communications and
He served as President of the
Foundation for the Disabled
and worked as Advertising
Director of Data
and TV Center.
Management board member
with experience in VC, PE
and M&A. Executive officer
at seed capital funds, investing
in Polish and international
Start-Ups. Warsaw School
of Economics graduate (MSc)
and Universiteit van Tilburg.
We present improved tumor targeting delivery system, carrying diagnostic radioisotope for PET or SPECT detectors.
Our technology key features:
- Based on safe polymer nanocarrier
- Nanoparticles accumulate inside tumor tissue due to enhanced permeation and retention through the leaky blood vessels
- Confirmed non-toxicity and biocompatibility
- Universal – for various cancer cell types
- Theranostic approach – nanoparticles for diagnostics, also with potential therapeutic use
- Precise diagnostics exploiting radioisotopes
More details about Technology will be available immediately after patent submission.